Will extend its sterile dosage form manufacturing capabilities
Famar is to acquire a plant in Madrid from sanofi-aventis
Famar plans to acquire a sanofi-aventis plant in Madrid, Spain to expand its sterile dose manufacturing capabilities and capacity.
The Athens, Greece-based firm said it would integrate the plant into its network of 11 pharmaceutical production sites across Europe, which includes distribution centres in France, Greece, Italy and The Netherlands.
The network provides development, manufacturing, packaging and logistics services for all dosage forms.
All employees at the Avenida de Leganes plant in Alcorcon, Madrid will be transferred to Famar.
The company said the plant, which produces solid and sterile forms including freeze drying, and currently supplies more than 50 markets, will provide a solid platform from which to develop its services.
The acquisition of the plant is also an opportunity for Famar to strengthen its ties with sanofi-aventis, originally made when the company acquired a plant in L’Aigle, France from the French drugmaker in 2001.
Famar also acquired a plant at Saint-Remy in France from Abbott in 2007, which is integrated to the L’Aigle business unit and has been developed as a centre for sterile and lyophilised production.
Once the deal has been finalised, sanofi-aventis will continue to source certain products from the site.
Famar said it has a ‘significant investment plan’ to expand the sterile capacities and services at the plant.
The transaction should be completed by the end of the second quarter.